MedKoo Cat#: 461329 | Name: Rilopirox

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rilopirox is a synthetic fungicidal antimycotic agent with hydrophobic characteristics.

Chemical Structure

Rilopirox
Rilopirox
CAS#104153-37-9

Theoretical Analysis

MedKoo Cat#: 461329

Name: Rilopirox

CAS#: 104153-37-9

Chemical Formula: C19H16ClNO4

Exact Mass: 357.0768

Molecular Weight: 357.79

Elemental Analysis: C, 63.78; H, 4.51; Cl, 9.91; N, 3.91; O, 17.89

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Rilopirox;
IUPAC/Chemical Name
6-((4-(4-chlorophenoxy)phenoxy)methyl)-1-hydroxy-4-methylpyridin-2(1H)-one
InChi Key
UDYUIWXQUBNDHC-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H16ClNO4/c1-13-10-15(21(23)19(22)11-13)12-24-16-6-8-18(9-7-16)25-17-4-2-14(20)3-5-17/h2-11,23H,12H2,1H3
SMILES Code
O=C1C=C(C)C=C(COC2=CC=C(OC3=CC=C(Cl)C=C3)C=C2)N1O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 357.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Raether W, Hänel H. Rilopirox--a new hydroxypyridone antifungal with fungicidal properties. Mycoses. 1990 Apr;33(4):191-202. PubMed PMID: 2233892. 2: Nenoff P, Haustein UF. In vitro susceptibility testing of Malassezia furfur against rilopirox. Skin Pharmacol. 1997;10(5-6):275-80. PubMed PMID: 9449166. 3: Hrabé de Angelis M, Dannhorn DR, Hänel H, Kirchner C. Effects of rilopirox on rabbit blastocysts in a protein-free in vitro culture under different culture conditions. Arzneimittelforschung. 1994 May;44(5):674-8. PubMed PMID: 8024647. 4: Braga PC, Maci S, Dal Sasso M, Piatti G, Bohn M. Alterations in surface morphology of Candida albicans produced by rilopirox: a scanning electron microscopy study. J Chemother. 1995 Dec;7(6):519-24. PubMed PMID: 8667036. 5: Nenoff P, Taneva E, Pfeil B, Oswald U, Haustein UF. In vitro activity of rilopirox against fluconazole-susceptible and fluconazole-resistant Candida isolates from patients with HIV infection. Mycoses. 1999 Apr;42(1-2):55-60. PubMed PMID: 10394849. 6: Kruse R, Hengstenberg W, Hänel H, Raether W. Studies for the elucidation of the mode of action of the antimycotic hydroxypyridone compound, rilopirox. Pharmacology. 1991;43(5):247-55. PubMed PMID: 1664523. 7: Braga PC, Dal Sasso M, Maci S, Piatti G, Dannhorn DR, Bohn M. Inhibition of Candida albicans adhesiveness to human buccal and vaginal cells by sub-inhibitory concentrations of rilopirox. Arzneimittelforschung. 1995 Jan;45(1):84-7. PubMed PMID: 7893277. 8: Reitze HK, Dannhorn DR, Hänel H, Seitz KA. Ultrastructural investigations of Candida albicans after in vitro treatment with the new fungicidal agent rilopirox. Mycoses. 1993 Nov-Dec;36(11-12):385-95. PubMed PMID: 7935570. 9: Sigle HC, Schäfer-Korting M, Korting HC, Hube B, Niewerth M. In vitro investigations on the mode of action of the hydroxypyridone antimycotics rilopirox and piroctone on Candida albicans. Mycoses. 2006 May;49(3):159-68. PubMed PMID: 16681805. 10: Harada I, Mitsui K, Uchida K, Yamaguchi H. [The in vitro properties of a new hydroxypyridone antimycotic rilopirox, with special reference to its anti-Candida activity]. Jpn J Antibiot. 1999 Feb;52(2):146-52. Japanese. PubMed PMID: 10221179. 11: Braga PC, Maci S, Dal Sasso M, Bohn M. Experimental evidences for a role of subinhibitory concentrations of rilopirox, nystatin and fluconazole on adherence of Candida spp. to vaginal epithelial cells. Chemotherapy. 1996 Jul-Aug;42(4):259-65. PubMed PMID: 8804793. 12: Harada I, Mitsui K, Uchida K, Yamaguchi H. [In vitro antifungal activity of rilopirox, a new hydroxypyridone antimycotic agent]. Jpn J Antibiot. 1997 Feb;50(2):195-9. Japanese. PubMed PMID: 9100079. 13: Rubin AI, Bagheri B, Scher RK. Six novel antimycotics. Am J Clin Dermatol. 2002;3(2):71-81. Review. PubMed PMID: 11893219. 14: Korting HC, Grundmann-Kollmann M. The hydroxypyridones: a class of antimycotics of its own. Mycoses. 1997 Nov;40(7-8):243-7. Review. PubMed PMID: 9476505. 15: Hänel H, Smith-Kurtz E, Pastowsky S. [Therapy of seborrheic eczema with an antifungal agent with an antiphlogistic effect]. Mycoses. 1991;34 Suppl 1:91-3. German. PubMed PMID: 1840158. 16: Torres-Rodríguez JM. New topical antifungal drugs. Arch Med Res. 1993 Winter;24(4):371-5. Review. PubMed PMID: 8118161. 17: Nenoff P, Reinl P, Haustein UF. [The yeast fungus Malassezia: pathogen, pathogenesis and therapy]. Hautarzt. 2001 Jan;52(1):73-86. Review. German. PubMed PMID: 11220247.